Posted by Michael Wonder on 12 Jan 2025
Mersana Therapeutics announces additional FDA fast track designation granted to emiltatug ledadotin (XMT-1660)
10 January 2025 - Mersana Therapeutics today announced the US FDA recently granted an additional fast track designation to XMT-1660.
The company also announced that the World Health Organization has approved emiltatug ledadotin as XMT-1660’s international non-proprietary name.
